For: | López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v7/i3/539.htm |
Number | Citing Articles |
1 |
Özgür Dağlı, Meliha Kasapoğlu aksoy. Hepatitis B and hepatitis C infection prevalence in ankylosing spondylitis patients. Ortadoğu Tıp Dergisi 2018; 10(3): 297 doi: 10.21601/ortadogutipdergisi.390938
|
2 |
Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances 2019; 3(21): 3241 doi: 10.1182/bloodadvances.2019000811
|
3 |
Bryan R. Cobb, Alexandra Valsamakis, Randall T. Hayden, Donna M. Wolk, Karen C. Carroll, Yi-Wei Tang. Chronic Hepatitis B, C, and D. Microbiology Spectrum 2016; 4(4) doi: 10.1128/microbiolspec.DMIH2-0025-2015
|
4 |
Claudio Bonifati, Viviana Lora, Dario Graceffa, Lorenzo Nosotti. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World Journal of Gastroenterology 2016; 22(28): 6444-6455 doi: 10.3748/wjg.v22.i28.6444
|
5 |
Francesco Saccà, Chiara Pane, Anna De Rosa, Margherita Matarazzo, Vincenzo Brescia Morra. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Neurological Sciences 2017; 38(3): 501 doi: 10.1007/s10072-016-2726-3
|
6 |
Heri Krisnata Ginting, Soebagijo Adi. A CASE OF THYROTOXIC PERIODIC PARALYSIS AND MODERATE TO SE- VERE GRAVE’S OPHTHALMOPATHY REQUIRING INTRAVENOUS STEROID THERAPY WITH A COMORBIDITY OF CHRONIC HEPATITIS B INFECTION. Current Internal Medicine Research and Practice Surabaya Journal 2022; 3(2): 47 doi: 10.20473/cimrj.v3i2.32528
|
7 |
Bryan R. Cobb, Alexandra Valsamakis. Diagnostic Microbiology of the Immunocompromised Host. 2016; : 69 doi: 10.1128/9781555819040.ch3
|
8 |
David Alexanian, Aleksandr Birg, Nicholas Volpicelli, Joseph Glass, Denis McCarthy. Latent Hepatitis Virus Reactivation Due to Drug Reaction: DRESSed to Kill?. Digestive Diseases and Sciences 2018; 63(5): 1143 doi: 10.1007/s10620-018-5028-1
|
9 |
Rebecca L. Yanovsky, Michael McLeod, A. Razzaque Ahmed. Treatment of pemphigus vulgaris: part 1 – current therapies. Expert Review of Clinical Immunology 2019; 15(10): 1047 doi: 10.1080/1744666X.2020.1672535
|
10 |
Sydney Chi‐Wai Tang, Andrew Kui‐Man Wong, Siu‐Ka Mak. Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology. Nephrology 2019; 24(S1): 9 doi: 10.1111/nep.13500
|
11 |
Jing Fang, Wenge Li, Min Tan, Wen Chen, Cong Zhang, Wenbo Wang, Qianqian Xu, Xinzhen Guo. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. International Urology and Nephrology 2018; 50(9): 1653 doi: 10.1007/s11255-018-1867-0
|
12 |
Rossella Talotta, Fabiola Atzeni, Piercarlo Sarzi Puttini. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. BMC Pharmacology and Toxicology 2016; 17(1) doi: 10.1186/s40360-016-0060-2
|
13 |
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José M. Peña, José V. Fernández-Montero, Laura Benítez, Isabella Esposito, Pablo Barreiro. Emerging Challenges in Managing Hepatitis B in HIV Patients. Current HIV/AIDS Reports 2015; 12(3): 344 doi: 10.1007/s11904-015-0275-7
|